Polski     English


Current Size: 87%

Godło Polski

MUW receives ERIC certificate

The Medical University of Warsaw has been certified by the ERIC (European Research Initiative on Chronic Lymphocytic Leukemia), which authorizes the study of mutations in the TP53 gene with advanced NGS (next-generation sequencing) technology. WUM is the only center in Poland with certification for Sanger sequencing and NGS.  Genetic testing is conducted by Dr. Tomasz Stokłosa and his team at the Department of Immunology in cooperation with prof. Rafał Płoski and his team at the Department of Medical Genetics.

Chronic lymphocytic leukemia (CLL) is associated with a highly heterogeneous disease course. This heterogeneity is partly explained by the diverse genetic aberrations identified in CLL patients. TP53 aberrations belong to the strongest prognostic and predictive markers. Early detection of TP53 aberrations is therefore key in guiding treatment decisions in CLL.

The use of NGS technology and related certificates enabled WUM to join Polish Adult Leukemia Group’s (PALG) project in the field of modern genetic research.  The project "Evaluation of genetic and immunological prognostic factors and response to treatment of patients with refractory and recurrent chronic lymphocytic leukemia, especially those treated with B receptor inhibitors - cellular" is coordinated by the Institute of Hematology and Blood Transfusion

European Research Initiative on Chronic Lymphocytic Leukemia: http://www.ericll.org/certifiedcentres-poland/

European Research Initiative on CLL: ERIC represents an European organization devoted to developing and coordinating experimental and clinical research in Europe and beyond by creating common standards with regard to the diagnostic and therapeutic management of chronic lymphocytic leukemia (CLL) patients.

TP53 Certificate PASSED (NGS) - ERIC.jpg
Warszawski Uniwersytet Medyczny na Facebook
Warszawski Uniwersytet Medyczny na Instagram
Warszawski Uniwersytet Medyczny na Youtube
Warszawski Uniwersytet Medyczny na Twitter